

# Contents

## Part I. Innate Immunity in Autoimmune Diseases

### 1. Innate Immunity in Experimental Autoimmune Myocarditis

*Ziya Kaya and Noel R. Rose*

1. Introduction	1
2. Experimental Models of Myocarditis in Mice	2
2.1. Coxsackievirus B3 (CB3)-Induced Autoimmune Myocarditis	2
2.2. Cardiac Myosin-Induced Autoimmune Myocarditis	2
2.3. Peptide-Induced Myocarditis	3
3. Susceptibility to Myocarditis	3
4. Mouse Genotype	4
5. Innate Immune System and Myocarditis	5
5.1. Complement and Myocarditis	6
5.2. NK Cells and Myocarditis	8
5.3. Cytokines and Myocarditis	8
5.4. Chemokines and Myocarditis	10
6. Conclusions	11
Acknowledgments	11
References	12

### 2. Toll-like Receptor 9 and Autoimmunity

*Paul N. Moynagh*

1. Introduction	17
2. TLRs as Receptors for Pathogen-Associated Molecules	17
3. TLR9 and the Immunostimulatory Effects of Bacterial DNA	18
4. TLR9 and Intracellular signaling	18
5. CpG Sequences in Self-DNA Trigger Autoantibody Production	20
6. TLR9 as a Target for Regulating RF Production	21
7. Concluding Remarks	22
Acknowledgments	22
References	22

### 3. C-Reactive Protein as a Regulator of Autoimmune Disease

*Terry W. Du Clos and Carolyn Mold*

1. Introduction	27
2. Structural Features of CRP	27
3. CRP as an Acute-Phase Reactant	28
4. CRP Interaction with Nuclear Antigens	29
5. CRP, SAP, and Nuclear Antigen Clearance	30
6. CRP Genetics and Autoimmunity	31
7. CRP Levels in Human SLE	31
8. CRP in Animal Models of Autoimmunity	32
9. CRP in Immune Complex Nephritis	33
10. CRP in Inflammation	34
11. Identification of FcγR as CRP Receptors	34
12. Role of FcγR in CRP Effects on Inflammation	35
13. Essential Role of IL-10 in Anti-inflammatory Activities of CRP	37
14. Current Perspective on CRP in Autoimmune Disease	37
References	38

### 4. NKT Cells and Autoimmune Type 1 Diabetes

*Shabbir Hussain, Dalam Ly, Melany Wagner, and Terry L. Delovitch*

1. Introduction	43
2. Type 1 Diabetes	44
3. NKT Cells	44
4. Role of iNKT Cells in the Pathogenesis of Type 1 Diabetes	45
4.1. iNKT Cell Deficiency and T1D	45
4.2. iNKT Cell Activation Induces Protection against Type 1 Diabetes	47
5. Future Directions	49
Acknowledgments	50
References	50

## Part II. Genetics of Autoimmune Diseases

### 5. The Genetics of Human Autoimmune Diseases

*Marta E. Alarcón-Riquelme*

1. Introduction	55
2. Analysis of the Genetics of Complex Diseases	56
2.1. Linkage Analysis	56
2.2. Association Analysis	57
2.3. Combining Linkage and Association	58
3. Genetic Analysis in Autoimmunity	58
3.1. Genome Scans and Linkage Analysis in Autoimmune Diseases	58
3.2. Autoimmune Diabetes (T1D)	58
3.3. Multiple Sclerosis (MS)	59

3.4. Rheumatoid Arthritis (RA) . . . . .	60
3.5. Crohn's Disease (CD) and Ulcerative Colitis (UC) . . . . .	61
3.6. Systemic Lupus Erythematosus (SLE) . . . . .	62
3.7. Genes Shared between Autoimmune Diseases . . . . .	63
References . . . . .	64

## 6. Failure to Maintain T Cell DNA Methylation and Chromatin Structure Contributes to Human Lupus

*Donna Ray and Bruce Richardson*

1. Introduction . . . . .	69
2. DNA Methylation, Chromatin Structure, and Gene Expression . . . . .	70
3. DNA Methylation and Drug-Induced Lupus . . . . .	73
3.1. DNA Methylation and Autoimmunity . . . . .	73
3.2. DNA Methylation and Drug-Induced Lupus . . . . .	75
3.3. T Cell Genes Affected by DNA Methylation Inhibitors . . . . .	76
4. Aberrant T cell DNA Methylation, Gene Expression, and Cellular Function in Idiopathic Lupus . . . . .	77
4.1. DNA Methylation . . . . .	77
4.2. Gene Expression and Cellular Function . . . . .	78
5. Conclusions . . . . .	80
References . . . . .	81

## 7. Complement Components C4A and C4B in Human Lupus

*Yan Yang, Erwin K. Chung, Karl Lhotta, Yee Ling Wu, Gloria C. Higgins, Robert M. Rennebohm, Lee A. Hebert, Daniel J. Birmingham, Brad H. Rovin, and C. Yung Yu*

1. Introduction . . . . .	85
2. Diversities of Complement Components C4A and C4B in Human Populations . . . . .	86
2.1. Dichotomy in Gene Sizes, Polygenes, and RCCX Module Variants . . . . .	86
2.2. Diversity of Human C4A and C4B Proteins . . . . .	87
2.3. Genetic Determinants of C4 Plasma/Serum Protein Levels . . . . .	89
3. Complete Deficiencies of C4A and C4B in SLE and Immune-Complex Diseases . . . . .	90
3.1. Molecular Basis of Complete C4 Deficiency . . . . .	90
3.2. Impairment of Immune Response in C4-Deficient Patients . . . . .	91
4. Deficiencies of C4A or C4B in Human SLE . . . . .	92
4.1. Low Complement Activity and C4 Protein Concentrations in SLE . . . . .	92
4.2. Homozygous or "partial" Deficiency of C4A in SLE across multiple ethnic groups . . . . .	92
4.3. Deficiency of C4B in SLE Patients from Spanish, Mexican, and Australian Aborigines . . . . .	93
4.4. Partial Deficiencies versus Polygenic Variations of C4A and C4B . . . . .	94
5. Concluding Remarks and Perspectives . . . . .	94
Acknowledgments . . . . .	95
References . . . . .	96

## 8. Non-MHC Genetic Polymorphisms with Functional Importance for Human Myasthenia Gravis

*Ann Kari Lefvert*

1. Introduction . . . . .	101
2. Pro- and Anti-inflammatory Cytokines in MG . . . . .	102
2.1. Association of MG to the High Secretory Alleles of TNF- $\alpha$ . . . . .	102
2.2. Functional Implications of the Association with the TNF- $\alpha$ -308 A2 Allele . . . . .	103
2.3. Association of MG to the high secretory Allele of IL-1 $\beta$ . . . . .	103
2.4. Functional Implications of the Association with the IL-1 $\beta$ TaqI RFLP A2 Allele . . . . .	104
2.5. Lack of Associations of MG to Genetic Variants of IL-4 and IL-6 . . . . .	105
2.6. IL-10 Is Associated to MG with High Autoantibody Levels . . . . .	105
3. The $\beta$ 2-Adrenergic Receptor in MG . . . . .	105
4. The T Cell Receptor Cofactor CTLA-4 in MG . . . . .	106
4.1. Association to MG with Thymoma and Increased Activation of the Immune System . . . . .	106
4.2. Functional Correlates to the Genetic Variants of <i>Ctla-4</i> . . . . .	107
4.3. The C/T SNP at -318 . . . . .	108
4.4. The A/G SNP in CDS1 . . . . .	108
4.5. Promoter SNPs -1772 (C/T) and -1661 (A/G) . . . . .	108
4.6. CTLA-4 and Thymomas . . . . .	109
4.7. <i>Ctla-4</i> (AT)n Is Associated to ADCC . . . . .	109
5. Conclusions . . . . .	109
Acknowledgments . . . . .	110
References . . . . .	110

## Part III. Triggers of the Autoimmune Attack

### 9. Rheumatic Heart Disease: Molecular Basis of Autoimmune Reactions Leading to Valvular Lesions

*Luiza Guilherme, Kellen Faé, and Jorge Kalil*

1. Introduction . . . . .	115
2. The Etiopathogenic Agent: <i>Streptococcus Pyogenes</i> . . . . .	116
3. Genetic Susceptibility . . . . .	116
4. Molecular Mimicry and RF/RHD . . . . .	118
4.1. The Humoral Immune Response . . . . .	119
4.2. The Cellular Immune Response . . . . .	119
4.3. Humoral and Cellular Immune Responses Interface in RF/RHD . . . . .	121
4.4. T Cell Receptor (TCR) Usage . . . . .	121
5. Cytokines . . . . .	122
6. Animal Models . . . . .	122
7. Conclusions . . . . .	123
References . . . . .	123

## 10. Autoimmunity against Desmogleins in Pemphigus Vulgaris

*Christian Veldman and Michael Hertl*

1. Introduction . . . . .	127
2. Clinical Phenotype of Pemphigus Vulgaris . . . . .	128
3. Epidemiology of Pemphigus and Association with HLA Class II Alleles . . . . .	128
4. Pathogenesis of Pemphigus . . . . .	128
5. Autoantibody Reactivity against Desmogleins . . . . .	129
6. Autoreactive T Lymphocytes in Pemphigus . . . . .	132
7. Regulatory T Lymphocytes in Pemphigus . . . . .	134
8. Passive Animal Models of Pemphigus Vulgaris . . . . .	135
9. Active Animal Model of Pemphigus Vulgaris . . . . .	135
10. Conclusions . . . . .	135
References . . . . .	136

## 11. The Molecular Basis of Celiac Disease

*Liesbeth Spaenij-Dekking and Frits Koning*

1. Introduction . . . . .	141
2. T Cell Recognition of Gluten Peptides . . . . .	142
3. The Specificity of tTG Is Linked to Gluten Toxicity . . . . .	145
4. Additional T cell Stimulatory Peptides in Barley, Rye, and Oats . . . . .	145
5. The HLA Gene Dose Effect Is Linked to the Level of Gluten Presentation . . . . .	146
6. Generation of Safer Foods for Patients . . . . .	147
7. A Hypothesis for Disease Development . . . . .	147
8. Future Research and Perspectives . . . . .	148
Acknowledgments . . . . .	149
References . . . . .	149

## 12. Intrathymic Expression of Neuromuscular Acetylcholine Receptors and the Immunopathogenesis of Myasthenia Gravis

*Arnold I. Levinson, Yi Zheng, Glen Gaulton, and Decheng Song*

1. Introduction . . . . .	151
2. Evidence Supporting the Role of the Thymus in MG Pathogenesis . . . . .	152
3. Expression of Neuromuscular AChRs by Thymic Cells . . . . .	153
4. The Thymus and Central Immune Tolerance . . . . .	157
5. The Thymus and T Cell Trafficking . . . . .	157
6. Development of an Experimental Model to Examine Peripheral T Cell Entry and Activation in the Thymus . . . . .	158
7. Conclusions . . . . .	160
Acknowledgments . . . . .	160
References . . . . .	161

## Part IV. Targets of the Autoimmune Attack

### 13. Autoantibodies and Nephritis: Different Roads May Lead to Rome

*Paola Migliorini, Consuelo Anzilotti, Laura Caponi, and Federico Pratesi*

1. Introduction . . . . .	165
2. Acute Poststreptococcal Glomerulonephritis . . . . .	167
3. Goodpasture's Syndrome . . . . .	169
4. Lupus Nephritis . . . . .	170
5. Other Nephritogenic Autoantibodies . . . . .	174
6. Conclusions . . . . .	175
References . . . . .	176

### 14. Estrogen, Interferon-Gamma, and Lupus

*S. Ansar Ahmed and Ebru Karpuzoglu-Sahin*

1. Introduction . . . . .	181
2. Estrogen and Lupus: Human and Animal Studies . . . . .	182
3. Mechanisms of Estrogen Effects on the Immune System . . . . .	185
3.1. Estrogen Exerts Its Biological Effects on Cells by Both Estrogen Receptor-Dependent and -Independent Mechanisms . . . . .	185
3.2. Estrogen Alterations of B cells . . . . .	189
3.3. Estrogen Effects on Cytokines . . . . .	189
4. IFN $\gamma$ in SLE and Other Autoimmune Diseases . . . . .	190
5. Conclusions . . . . .	191
Acknowledgments . . . . .	192
References . . . . .	193

### 15. Extent of Regulatory T Cell Influence on Major Histocompatibility Complex Class II Gene Control of Susceptibility in Murine Autoimmune Thyroiditis

*Yi-chi M. Kong, Gerald P. Morris, and Chella S. David*

1. Introduction . . . . .	197
2. Major Histocompatibility Complex (MHC) Class II Gene Control of Susceptibility . . . . .	198
3. Establishment of CD4 <sup>+</sup> T Cells as Mediators of Induced Resistance . . . . .	199
3.1. Protection from EAT Induction by Elevating Circulatory Thyroglobulin Level . . . . .	199
3.2. CD4 <sup>+</sup> Regulatory T Cells as Mediators of Induced Resistance . . . . .	200
3.3. Effect of Cytokines on CD4 <sup>+</sup> Regulatory T Cell Induction and Function . . . . .	200
4. CD25 Expression on CD4 <sup>+</sup> Regulatory T Cells in Induced Resistance . . . . .	201
4.1. Abrogation of Established Tolerance by CD4 <sup>+</sup> CD25 <sup>+</sup> T Cell Depletion . . . . .	201

4.2. Interference with CD4 <sup>+</sup> CD25 <sup>+</sup> Regulatory T Cell Function by Cross-Linking TNFR Family Molecules . . . . .	203
5. Naturally Existing CD4 <sup>+</sup> CD25 <sup>+</sup> T Cells as Peripheral Barrier to Autoimmune Thyroiditis . . . . .	204
6. T Cell Regulation and MHC Restriction . . . . .	204
7. Conclusion . . . . .	206
Acknowledgment . . . . .	206
References . . . . .	206

## 16. The Role of Autoimmunity in Multiple Sclerosis

*Monika Bradl and Hans Lassmann*

1. Introduction . . . . .	209
2. The “Autoimmune Hypothesis” of MS . . . . .	210
3. The Multiple Facets of Multiple Sclerosis . . . . .	210
3.1. The Clinical Spectrum of MS . . . . .	210
3.2. The Pathological Spectrum of MS . . . . .	211
3.3. Evidence for T Cell–Mediated Autoimmunity . . . . .	212
3.4. Evidence for B Cell– or Antibody-Mediated Autoimmunity . . . . .	215
3.5. Evidence for Autoimmunity from Immunotherapies of MS . . . . .	216
4. The Triggers for Autoimmune Reactions in MS Patients . . . . .	216
4.1. Autoimmune Reactions Caused by a Defect in Immune Regulation . . . . .	217
4.2. Autoimmune Reactions Caused by Infections . . . . .	218
5. Protective Autoimmunity . . . . .	220
6. What Remains of the “Autoimmune Hypothesis” of MS? . . . . .	220
References . . . . .	221

## Part V. Immune Receptor Signaling Pathways

### 17. Crippled B Lymphocyte Signaling Checkpoints in Systemic Autoimmunity

*Moncef Zouali*

1. Introduction . . . . .	227
2. B Lymphocytes Participate in Both Innate and Adaptive Immunity . . . . .	228
3. The Critical Role of B Cells in Autoimmunity . . . . .	229
4. B Cell Receptor–Mediated Signaling Checkpoints . . . . .	230
5. Critical Regulators of B Cell Receptor Signaling . . . . .	231
6. Negative Regulators of B Cell Receptor–Mediated Signal Transduction . . . . .	234
7. Disrupted B Cell Signaling Pathways in Human Autoimmunity . . . . .	237
8. Conclusions . . . . .	239
References . . . . .	239

## 18. Disrupted T Cell Receptor Signaling Pathways in Systemic Autoimmunity

*Ana M. Blasini and Martín A. Rodríguez*

1. Introduction	245
2. Signaling Pathways in T Cells	246
3. T Cell Signaling Abnormalities in Systemic Autoimmune Disease	250
3.1. Signaling Abnormalities in Antigen-Presenting Cells and Autoimmune Disease	250
3.2. Signaling Abnormalities in T Cells and Autoimmune Disease	252
4. Conclusions	255
Acknowledgments	257
References	257

## 19. Immune Cell Signaling and Gene Transcription in Human Systemic Lupus Erythematosus

*Christina G. Katsiari and George C. Tsokos*

1. Introduction	263
2. Altered Pattern of Tyrosine Phosphorylation and Calcium Responses	264
3. TCR $\zeta$ Chain Deficiency	265
3.1. Impaired TCR $\zeta$ Chain Gene Transcription	266
3.2. Impaired Translation and Posttranscription Events	266
3.3. Impaired Posttranslational Functions	267
3.4. Oxidative Stress	267
3.5. Role of IFN $\gamma$	268
4. Mechanisms of Increased TCR/CD3-Mediated $[Ca^{2+}]_i$ Response in SLE T Cells	268
4.1. FcR $\gamma$ Chain Substitutes for Defective $\zeta$ Chain	268
4.2. Altered Composition and Dynamics of Lipid Rafts	269
5. Protein Kinase A (PKA) Function	271
6. Regulation of Transcription Determines Interleukin 2 Deficiency in SLE T Cells	272
7. Conclusions	274
References	275

## 20. Accumulation of Self-Antigens in Systemic Lupus Erythematosus

*Koji Yasutomo*

1. Introduction	279
2. T Cell in Human Lupus	280
3. Antigen Clearance and Autoimmunity	281
3.1. DNASE1-Deficient Patients: Gene Mutation and Clinical Features	281
3.2. DNASE1-Deficient Patients: Laboratory Findings	282
3.3. DNASE1-Deficient Patients: Effect on Autoreactivity	282
4. Defective Clearance of Self-Antigens in SLE	282
4.1. Evidence from Knockout Mice	282



4.2. Mechanisms of Accumulation of Self-Antigens in SLE .....	284
4.3. Clearance of Self-Antigens as a Therapeutic Strategy .....	286
References .....	286

## Part VI. Immunointervention Strategies

### 21. B Lymphocyte Depletion Therapy in Autoimmune Disorders: Chasing Trojan Horses

*Jonathan C. W. Edwards, Geraldine Cambridge, and Maria J. Leandro*

1. Introduction .....	291
2. Human Autoimmunity: An Abnormality of B Cell Function .....	291
2.1. A Brief History of Investigation of B and T Cell Autoreactivity in Human Autoantibody-Associated Diseases .....	292
2.2. Generation of Autoreactive T Cells .....	293
2.3. Autoantibodies as Effector Molecules .....	294
2.4. Autoantibodies as Trojan Horse Immunomodulators .....	294
3. Clinical Significance of the Trojan Horse Concept .....	297
3.1. Effector Mechanisms in RA .....	298
3.2. Logistics of B Cell Depletion .....	299
3.3. Anti-CD20 Therapeutic Agents .....	299
3.4. Rituximab .....	300
3.5. Efficacy .....	301
3.6. Failure of Seronegative Disease to Respond .....	302
3.7. Adverse Events Associated with BLyD .....	302
3.8. Repeated Cycles of B Cell Depletion .....	303
4. Do Data from BLyD Support the Trojan Horse Concept? .....	303
4.1. Autoantibody Levels Fall Selectively Compared with Antimicrobial and Total Immunoglobulin Levels .....	303
4.2. Total Immunoglobulin Levels May Fall after Repeat Cycles .....	304
4.3. Clinical Response Follows Serological Response, not B Cell Numbers ..	305
4.4. The Kinetics of Relapse Follow Autoantibody Rises Rather than B Cell Return .....	305
4.5. Why Are There Two Patterns of Relapse? .....	306
5. Conclusions .....	306
References .....	309

### 22. B lymphocyte Stimulator (BLyS) and Autoimmune Rheumatic Diseases

*William Stohl*

1. Introduction .....	313
2. BLyS and Its Receptors .....	313
2.1. General Biology .....	313

2.2. <i>In Vivo</i> Deficiency of BLyS or Its Receptors	315
2.3. Supranormal Levels of BLyS <i>In Vivo</i>	316
2.4. APRIL and Its Relevance to BLyS	318
3. BLyS Antagonism as a Therapeutic Modality	319
3.1. Mouse Models	319
3.2. The Human Experience	320
3.3. Which Patients Are Candidates for BLyS Antagonist Therapy?	321
3.4. Concluding Comments	322
References	322

## **23. Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments**

*Pierre Miossec*

1. Introduction	329
2. TNF $\alpha$ and Its Receptors	330
3. Mode of Action of the Specific TNF $\alpha$ Inhibitors	331
4. The Local and Systematic Effects of TNF $\alpha$ Inhibition	332
5. Understanding the Side Effects of TNF $\alpha$ Inhibitors	335
6. Other Cytokine Inhibitors	336
7. Other Cytokines as Treatment Targets	337
8. Targeting One or More than One Cytokine	337
9. Understanding the Heterogeneity of the Response to TNF $\alpha$ Inhibitors	338
10. Autoimmune Manifestations with Cytokine Administration	338
11. Conclusions	341
References	341

## **24. Hematopoietic Stem Cell Transplantation for the Treatment of Severe Autoimmune Diseases**

*Alan Tyndall and Paul Hasler*

1. Introduction	347
2. Autoimmune Disease Mechanisms	348
3. Coincidental AD in Patients Receiving HSCT for Another Indication	349
4. Animal Models	350
5. Treatment of Human Autoimmune Disease with Hematopoietic Stem Cell Transplantation	351
6. Systemic Sclerosis (SSc)	353
7. Rheumatoid Arthritis	353
8. Juvenile Idiopathic Arthritis	354
9. Systemic Lupus Erythematosus	354
10. Prospective Randomized Controlled Clinical Trials	355
11. Open Issues	356
11.1. Allogeneic HSCT	356
11.2. Immune Reconstitution	357
11.3. Ablative Therapy without HSCT	358
12. Conclusions	359
References	359

## 25. Molecular Mimicry in Autoimmune Uveitis: From Pathogenesis to Therapy

*Gerhild Wildner, Maria Diedrichs-Moehring, and Stephan R. Thureau*

1. Introduction . . . . .	365
2. Retinal Autoantigens and Mimicry Peptides . . . . .	366
3. HLA Peptide B27PD in EAU . . . . .	367
4. Pathogenic and Tolerogenic Epitopes of the Retinal Peptide PDSAg and Its Mimotope B27PD . . . . .	368
5. Antigenic Mimicry of Retinal Autoantigen and Environmental Antigens . . . . .	370
6. Treatment of Uveitis Patients with Oral Peptide B27PD . . . . .	372
References . . . . .	374

## 26. Molecular Pathogenesis of the Antiphospholipid Syndrome: Toward Novel Therapeutic Targets

*Silvia S. Pierangeli, Mariano Vega-Ostertag, Azzudin E. Gharavi, and E. Nigel Harris*

1. Introduction . . . . .	377
2. Antiphospholipid Antibodies and Platelets . . . . .	378
2.1. Effects of aPL on Platelets <i>In Vitro</i> and <i>In Vivo</i> . . . . .	378
2.2. Hydroxychloroquine in aPL-mediated thrombosis . . . . .	379
2.3. Intracellular Events in aPL-Mediated Platelet Activation . . . . .	380
3. Antiphospholipid Antibodies and Endothelial Cells . . . . .	381
3.1. Effects of aPL on Endothelial Cells . . . . .	381
3.2. The Statins and Antiphospholipid Antibodies . . . . .	385
3.3. Activation of the Complement Cascade and Antiphospholipid Antibodies . . . . .	385
4. Conclusions . . . . .	386
Acknowledgement . . . . .	387
References . . . . .	388

## 27. A Novel Approach to the Prevention of Atherosclerosis

*Sun-Ah Kang and Marc Monestier*

1. Introduction . . . . .	393
2. Atherosclerosis . . . . .	393
2.1. Lesion Initiation . . . . .	394
2.2. Fatty Streak Formation . . . . .	395
2.3. Fibrous Plaques . . . . .	395
2.4. Plaque Rupture and Thrombosis . . . . .	396
3. Immune Cells in Atherosclerosis . . . . .	396
4. Cellular Immunity in Atherosclerosis . . . . .	397
5. Humoral Immunity in Atherosclerosis . . . . .	400
6. Vaccination or Immunoglobulin Administration in Atherosclerosis . . . . .	401
7. Conclusions . . . . .	402
References . . . . .	403

**28. Antigen-Specific Regulation of Autoimmunity***Amy E. Juedes and Matthias G. von Herrath*

1. Introduction . . . . .	407
2. Antigen-Specific Therapy . . . . .	408
3. Antigen-Induced Regulatory T cells . . . . .	408
4. Factors Involved in Treg Induction . . . . .	410
4.1. Mechanisms of Protection . . . . .	411
4.2. Application to Human Disease . . . . .	412
5. Conclusions . . . . .	414
References . . . . .	414
Index . . . . .	419



<http://www.springer.com/978-0-387-24533-1>

Molecular Autoimmunity

Zouali, M. (Ed.)

2005, XXVII, 440 p., Hardcover

ISBN: 978-0-387-24533-1